Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 22,700 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 22,700 shares of Electra Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The shares were acquired at an average price of $8.45 per share, with a total value of $191,815.00. Following the completion of the acquisition, the director directly owned 5,255,278 shares of the company’s stock, valued at $44,407,099.10. This represents a 0.43% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, November 9th, Orbimed Advisors Llc acquired 20,000 shares of Electra Therapeutics stock. The shares were bought at an average cost of $8.24 per share, with a total value of $164,800.00.
• On Friday, November 6th, Orbimed Advisors Llc acquired 49,416 shares of Electra Therapeutics stock. The shares were bought at an average cost of $7.85 per share, with a total value of $387,915.60.
• On Thursday, November 5th, Orbimed Advisors Llc bought 156,091 shares of Electra Therapeutics stock. The stock was bought at an average price of $7.31 per share, for a total transaction of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc bought 71,367 shares of Electra Therapeutics stock. The shares were bought at an average cost of $7.53 per share, for a total transaction of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc bought 245,113 shares of Electra Therapeutics stock. The shares were bought at an average cost of $7.86 per share, for a total transaction of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The shares were bought at an average cost of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Performance

Shares of NASDAQ ETRA opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Wall Street Analysts Forecast Growth

ETRA has been the subject of a number of analyst reports. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an “overweight” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 target price on the stock. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. HC Wainwright initiated coverage on shares of Electra Therapeutics in a report on Monday, October 26th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $33.50.

Key Electra Therapeutics News

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
• Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.